Anika Therapeutics | ANIK - Umsatzerlöse

Aktienkurs
14.76
Täglich Wechseln
-0.46 -3.02%
Monatlich
2.79%
Jährlich
8.21%
Q2 Prognose
14.36




Der Umsatz Veränderung Datum
Abbott USD 11.46B 90M 2025-12
Agenus USD 34.2M 3.97M 2025-12
Agios Pharmaceuticals USD 19.97M 7.07M 2025-12
Anika Therapeutics USD 30.62M 2.8M 2025-12
Arrowhead Research USD 264.03M 7.56M 2025-12
Enanta Pharmaceuticals USD 16.96M 50.68M 2024-12
Halozyme Therapeutics USD 451.76M 97.76M 2025-12
Heron Therapeutics USD 40.59M 2.38M 2025-12
Insmed USD 263.8M 121.8M 2025-12
Integra LifeSciences USD 434.9M 32.84M 2025-12
Intrexon USD 717K 511K 2024-06
J&J USD 24.6B 610M 2025-12
Karyopharm Therapeutics USD 34.08M 3.54M 2025-12
Ligand Pharmaceuticals USD 59.66M 55.8M 2025-12
MacroGenics USD 41.23M 31.61M 2025-12
Merit Medical Systems USD 393.9M 9.7M 2025-12
Rigel Pharmaceuticals USD 55.31M 18.47M 2024-09
Sangamo BioSciences USD 356K 125K 2024-06
Sanofi EUR 11.3B 1.13B 2025-12
Smith & Nephew USD 3.18B 353M 2025-12
Stryker USD 7.2B 1.14B 2025-12
Surmodics USD 29.57M 355K 2025-06
Veracyte USD 140.6M 8.7M 2025-12
Xencor USD 28.24M 7.24M 2025-12
Zimmer Biomet Holdings USD 2.24B 240M 2025-12